Its valuation is considered fairly valued, Institutional ownership is very high.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Virax Biolabs Group Ltd's Score
Industry at a Glance
Industry Ranking
315 / 501
Overall Ranking
651 / 4682
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Virax Biolabs Group Ltd Highlights
StrengthsRisks
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.33K.
Overvalued
The company’s latest PE is -0.36, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 263.20K shares, decreasing 16.85% quarter-over-quarter.
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Ticker SymbolVRAX
CompanyVirax Biolabs Group Ltd
CEOFoster (James)
Websitehttps://www.viraxbiolabs.com
FAQs
What is the current price of Virax Biolabs Group Ltd (VRAX)?
The current price of Virax Biolabs Group Ltd (VRAX) is 0.370.
What is the symbol of Virax Biolabs Group Ltd?
The ticker symbol of Virax Biolabs Group Ltd is VRAX.
What is the 52-week high of Virax Biolabs Group Ltd?
The 52-week high of Virax Biolabs Group Ltd is 3.200.
What is the 52-week low of Virax Biolabs Group Ltd?
The 52-week low of Virax Biolabs Group Ltd is 0.350.
What is the market capitalization of Virax Biolabs Group Ltd?
The market capitalization of Virax Biolabs Group Ltd is 2.42M.
What is the net income of Virax Biolabs Group Ltd?
The net income of Virax Biolabs Group Ltd is -6.06M.
Is Virax Biolabs Group Ltd (VRAX) currently rated as Buy, Hold, or Sell?
According to analysts, Virax Biolabs Group Ltd (VRAX) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Virax Biolabs Group Ltd (VRAX)?
The Earnings Per Share (EPS TTM) of Virax Biolabs Group Ltd (VRAX) is -1.625.